Denosumab: mechanism of action and clinical outcomes.
Hanley DA, Adachi JD, Bell A, Brown V. · 2012
Read Denosumab: mechanism of action and clinical outcomes. by Hanley DA, Adachi JD, Bell A, Brown V. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3549483.txt.
Introduction
A single antibody can switch off bone removal, and D. A. Hanley, J. D. Adachi, A. Bell, and V. Brown explain denosumab's mechanism and clinical record in this 2012 review. Osteoporosis drugs either slow the cells that dissolve bone or build new bone; the review contrasts denosumab with bisphosphonates, estrogen, and anabolic agents.
Denosumab is a fully human antibody that binds RANKL, the signal osteoclasts need to mature, work, and survive. Blocking it cuts bone resorption. Bisphosphonates instead lodge in bone mineral and poison mature osteoclasts directly. Those different mechanisms shape how fast each drug acts and how fully its effect reverses after stopping, which matters when clinicians choose and sequence therapy.
Catalog record
| CREATOR | Hanley DA, Adachi JD, Bell A, Brown V. |
|---|---|
| YEAR | 2012 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Denosumab: mechanism of action and clinical outcomes By D A Hanley, J D Adachi, A Bell, V Brown Published in: International Journal of Clinical Practice DOI: 10.1111/ijcp.12022 ABSTRACT Abstract Aims To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and anabolic osteoporosis treatments. Methods Published papers related to the mechanism of action of approved osteoporosis treatments were sought through MEDLINE searches. Findings Osteoporotic fractures carry a substantial burden of morbidity and mortality, but pharmacotherapy can prevent such fractures in high-risk individuals. Antiresorptive drugs (e.g. bisphosphonates, oestrogen, denosumab) reduce bone turnover by distinct mechanisms. Denosumab, a recently approved therapy, is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. In contrast, bisphosphonates bind bone mineral, where they are absorbed by mature osteoclasts, inducing osteoclast apoptosis and suppressing resorption. These differences in mechanism influence both the onset and reversibility of treatment. Discussion Effective pharmacotherapy is necessary for patients at high risk of fracture. Among the treatment options for postmenopausal osteoporosis, there are significant differences in mechanism and dosing. Denosumab acts by a novel mechanism and is administered twice yearly by subcutaneous injection. Identified by Osteoporosis Canada Clinical Practice Guidelines as a first-line agent for treatment of postmenopausal osteoporosis, denosumab represents an important addition to our treatment options. Review criteriaStudies and review articles related to therapies for postmenopausal osteoporosis were sought via electronic databases and were identified from key references within articles. Search terms and MeSH headings used included mechanism of action combined with the word osteoporosis and each of the following: denosumab, antiresorptive, bisphosphonate, parathyroid hormone and RANK ligand. No formal evaluation of level of evidence was conducted in developing this narrative review.Message for the clinicFractures carry a substantial burden of morbidity and mortality, but are preventable by pharmacotherapy in high-risk patients. Mechanistic differences between therapeutics used for postmenopausal osteoporosis have important implications for the timing and reversibility of treatment. Osteoporosis is a systemic skeletal disease that increases with age and is common among postmenopausal women (1–5). Characterised by reduced bone mineral density (BMD) and weakened bone structure (2,3,6–8), osteoporosis decreases bone resistance to low-energy trauma and increases bone fragility and fracture risk (6,8,9). Almost all pharmacological agents for osteoporosis specifically target the bone resorption component of bone remodelling pathways; they are therefore classified as anticatabolic or antiresorptive agents (e.g. the bisphosphonates etidronate, alendronate, risedronate and zoledronic acid; oestrogen and the selective oestrogen receptor modulator (SERM) raloxifene; salmon calcitonin; and denosumab). The only anabolic agent currently available is teriparatide (7). These treatments reduce the risk of osteoporotic fractures and stabilise or increase bone mass and strength (10). This article aims to review the mechanisms of action of pharmacological therapies for osteoporosis and to clarify the differences between the bisphosphonates and denosumab, a newly approved antiresorptive agent with a novel mechanism of action (7,11). Denosumab is a fully human monoclonal antibody that binds RANKL, preventing RANKL from activating RANK, its receptor on the osteoclast surface (11). With reduced RANK–RANKL binding, osteoclast formation, function and survival are inhibited, bone resorption decreases and bone mass increases (11–13). FINDINGS The prevalence of osteoporosis and the care gap Osteoporotic fractures account for approximately 80% of all fractures occurring in postmenopausal women (14). Based on data from 2000 to 2005, it is estimated that more than 138,000 such fractures occur annually in Canada (15). In Ontario, more than half a million individuals were estimated to have osteoporosis in 2005, leading to approximately 57,000 osteoporosis-related fractures per year, along with $500 million in hospitalisation and long-term care costs (16). Incidence of osteoporotic hip fracture (approximately 21,000–25,000 per year in Canada) (15,17) is similar to that of breast cancer, heart attack or stroke (15). Such fractures are associated with a 25% risk of death within the following year, with continued elevated mortality in the second year following the event. Vertebral fracture, which is still more common (approximately 37,000 per year), is likewise associated with significantly increased mortality in the first and second year after the event (15). In a prospective study, Papaioannou et al. found that men and women over 50 years of age with hip fractures showed quality-of-life (QoL) deficits, particularly affecting mobility, ambulation and self-care (4). Deficits increased with the number of fractures and were similar to those in other chronic conditions, such as diabetes, arthritis and lung disease (18). According to a meta-analysis of eight studies, an overall 10% reduction in mortality is achievable with osteoporosis pharmacotherapy; this benefit is clearest for older, frailer individuals at high risk of fracture (19). When used as prescribed, pharmacological agents also offer significant QoL improvement among older women at risk of fracture (20). Despite abundant evidence of the high burden of mortality and morbidity imposed by osteoporosis in older Canadian women, and despite the clear benefits of pharmacotherapy in higher risk women (14), a care gap remains in the identification and management of this disease. A Quebec-based prospective study, for instance, showed that < 20% of women with incident osteoporotic fractures were prescribed pharmacotherapy for osteoporosis during the 6–8 months following the event (21). Osteoporosis and cell biology of the bone Normal bone remodelling is modulated by local and systemic regulators (22). Bone resorption and formation are normally in balance, enabling the repair of microdamage, maintenance of calcium homoeostasis and a stable bone mass (23). Bone is continually remodelled by the interaction of osteoclasts (which resorb the existing bone) and osteoblasts (which form new bone matrix). As shown in Figure 1, these two cell types work together with resident bone osteocytes in the basic multicellular units (BMUs) that carry out bone remodelling (1,9,24). [Figure: Resorption of old bone matrix and deposition of mineral into new bone are linked. Osteocytes, osteoblasts and osteoclasts are the main cells of the BMU of remodelling bone. BMUs like the one depicted here occur by the millions throughout the skeleton. They carry out the sequential resorption of old bone matrix and deposition/mineralisation of new bone. Osteocytes form a network of interconnected cells occupying lacunae (pits) within the mineralised bone tissue. Osteocytes are derived from osteoblasts (bone-forming cells) that were buried as new bone tissue formed, and they direct bone remodelling in response to mechanical strain and other stimuli. Osteocytes and osteoblasts initiate bone remodelling and start the process of bone resorption by releasing RANKL, which binds to RANK on osteoclasts and osteoclast precursors, activating these cells. Osteoblasts also produce OPG, which suppresses bone turnover. OPG binds to RANKL, preventing it from interacting with RANK. Activation of bone remodelling in a BMU therefore depends on the balance between RANKL and OPG. Adapted from, with permission of John Wiley & Sons, from Denosumab: Mechanism of Action and Clinical Outcomes, Sundeep Khosla, Jennifer J Westendorf, Merry Jo Oursler, 118, 2, 2008; permission conveyed through Copyright Clearance Center Inc.] Bone loss and structural damage occur when the extent of bone resorption within a BMU exceeds that of bone formation (negative bone balance) (24). An important cause of negative bone balance is menopause, when falling oestrogen production leads to an increase in RANKL secretion by osteoblasts and osteocytes,